Results 21 to 30 of about 6,730 (183)

The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis [PDF]

Blood, 2015
Key Points The c-Mpl activity in downstream signaling and in platelet homeostasis can be functionally separated. The c-Mpl platelet homeostasis depends on correct processing and surface expression of the receptor, whereas downstream signaling does not.
Clemens, Stockklausner, Anne-Christine, Klotter, Nicole, Dickemann, Isabelle N, Kuhlee, Christin M, Duffert, Carolin, Kerber, Niels H, Gehring, Andreas E, Kulozik   +7 more
openaire   +2 more sources

Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway

Haematologica, 2010
Background Platelet-derived growth factor is involved in the regulation of hematopoiesis. Imatinib mesylate, a platelet-derived growth factor receptor inhibitor, induces thrombocytopenia in a significant proportion of patients with chronic myeloid ...
Jie Yu Ye, Godfrey Chi Fung Chan, Liang Qiao, Qizhou Lian, Fan Yi Meng, Xue Qun Luo, Levon M. Khachigian, Ming Ma, Ruixia Deng, Jian Liang Chen, Beng H. Chong, Mo Yang   +11 more
doaj   +1 more source

SH2-inositol phosphatase 1 negatively influences early megakaryocyte progenitors. [PDF]

PLoS ONE, 2008
The SH2-containing-5'inositol phosphatase-1 (SHIP) influences signals downstream of cytokine/chemokine receptors that play a role in megakaryocytopoiesis, including thrombopoietin, stromal-cell-derived-Factor-1/CXCL-12 and interleukin-3.
Lia E Perez, Caroline Desponts, Nancy Parquet, William G Kerr   +3 more
doaj   +1 more source

Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling. [PDF]

PLoS ONE, 2011
BACKGROUND: Mutations in the thrombopoietin receptor (MPL) may activate relevant pathways and lead to chronic myeloproliferative neoplasms (MPNs). The mechanisms of MPL activation remain elusive because of a lack of experimental structures.
Tai-Sung Lee, Hagop Kantarjian, Wanlong Ma, Chen-Hsiung Yeh, Francis Giles, Maher Albitar   +5 more
doaj   +1 more source

Development of thrombopoietin receptor agonists for clinical use [PDF]

Journal of Thrombosis and Haemostasis, 2009
Thrombopoietin (TPO) is an essential hematopoietic cytokine for megakaryopoiesis. In 2002, we demonstrated that pegylated-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts in patients with chronic immune thrombocytopenic purpura (ITP) in a Phase I/II clinical trial.
Y, Ikeda, Y, Miyakawa
openaire   +2 more sources

H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets

Journal of Hematology & Oncology, 2016
Background Our previous pilot studies aimed to examine the role of hydrogen sulfide (H2S) in the generation of endothelial progenitor cells led to an unexpected result, i.e., H2S promoted the differentiation of certain hematopoietic stem/progenitor cells
Huan-Di Liu, Ai-Jie Zhang, Jing-Jing Xu, Ying Chen, Yi-Chun Zhu   +4 more
doaj   +1 more source

Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS

International Journal of Analytical Chemistry, 2020
Lusutrombopag is a second oral thrombopoietin (TPO) receptor agonist that selectively acts on human TPO receptors. In the study, UPLC-MS/MS was used to establish a selective and sensitive method to determine lusutrombopag with poziotinib as IS (internal ...
Bo Wang, Feifei Chen, Quan Zhou, Yunfang Zhou, Deru Meng, Peiwu Geng, Ailian Hua, Weiping Ji, Changxiong Wang, Shuanghu Wang, Liming Hu   +10 more
doaj   +1 more source

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation

mAbs, 2022
Although several antibody fragments and antibody fragment-fusion proteins produced in Escherichia coli (E. coli) are approved as therapeutics for various human diseases, a full-length monoclonal or a bispecific antibody produced in E.
Md Harunur Rashid
doaj   +1 more source

Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia [PDF]

Seminars in Hematology, 2013
Thrombopoietin (TPO) regulates thrombopoiesis through activation of TPO receptors on the megakaryocyte cell surface, resulting in increased platelet production. The TPO receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes.
Deborah, Siegal, Mark, Crowther, Adam, Cuker   +2 more
openaire   +2 more sources

Stanozolol and Danazol Have Different Effects on Hematopoiesis in the Murine Model of Immune-Mediated Bone Marrow Failure

Frontiers in Medicine, 2021
Background: Stanozolol and danazol are widely used in the treatment of aplastic anemia; however, their mechanisms of action are unclear.Methods: Bone marrow mononuclear cells from 10 patients newly diagnosed with aplastic anemia and 10 healthy volunteers
Hongmin Li, Zhangbiao Long, Tao Wang, Bing Han   +3 more
doaj   +1 more source